Xbiome Raises nearly $10 Million in Series B+ Round

Xbiome, which calls itself China’s first AI-based company that specializes in the development of gut microbiome, has raised a total of about $10 million in Series B+ round as investors pour money into firms developing products that promote healthy stomach bacteria.

This round of financing was led by Primavera Capital and Gaorong Capital, followed by Wuyuan Capital, Legend Capital, Yimei Capital and Yayi Capital.

The funds will be mainly used for the development of clinical trials of the team in 2021, the development of drug pipelines, and the continuous development and deepening of the existing technology platform. In this round of financing, China Renaissance Capital served as the exclusive financial advisor.

Xbiome is the first AI pharmaceutical company in China that specializes in intestinal micro-ecology. It is based on intestinal micro-ecology and relies on AI technology to accurately and personally manage the gut health of 1.3 billion people. 

Different from the traditional “cell-animal model – human body” medical research and development path, Xbiome uses an innovative research model and a unique drug research and development platform to “artificial intelligence + bioinformatics technology” and intestinal micro-ecology The combination of technologies has greatly improved the research and development efficiency and success rate of new drugs.

At present, Xbiome has completed the deployment of tumor immunotherapy, nervous system and immune diseases and other indications, and has four self-developed micro-ecological drug pipelines. Through clinical trials initiated by researchers, we have cooperated with medical institutions such as Peking University Cancer Hospital, Shanghai Xinhua Hospital, Southern Medical University Nanfang Hospital and other medical institutions to carry out intestinal microecology clinical research.

Primavera Capital Group is a China-based global investment firm, focusing on growth capital, buyout and control, and cross-border investments. Primavera seeks to create long-term value by working closely with portfolio companies to improve operational efficiency, competitiveness, and earnings growth.